AMD's New 2026 Price Target Implies a Double — If AI Spending Doesn't Hit a Wall First

AMD's New 2026 Price Target Implies a Double — If AI Spending Doesn't Hit a Wall First

DA Davidson analyst Gil Moreland didn't tweak his AMD forecast on Friday. He rebuilt it. The new 2026 price target reflects a near-doubling from current levels, anchored to a single bet: that AMD's data center business will sustain roughly 50% revenue growth as hyperscalers keep buying AI chips by the pallet.

The bull case isn't crazy. AMD's MI300X accelerators — the chips that compete directly with Nvidia's H100s for training and running AI models — are already shipping to Microsoft, Meta, and others at scale. While Nvidia grabs the magazine covers, AMD has been quietly taking share in the market for inference workloads, where cost-per-query matters more than raw benchmark scores. Moreland is pricing that momentum into a 2026 story, not a 2024 one.

The bear case is simple: AMD trades around 40x forward earnings, which leaves no room for a miss. If enterprise AI budgets get trimmed, if shipments slip a quarter, or if Nvidia launches next-gen hardware that widens the performance gap, that multiple compresses fast. The stock's consumer graphics division — still soft from the gaming downcycle — provides no cushion. One bad data center quarter and this target becomes a cautionary tweet.

Gobble's Take: AMD is the trade for investors who think Nvidia is too crowded — but at 40x earnings, you're paying for perfection in a market that rarely delivers it.

Source: Yahoo Finance

Ardelyx Dropped 20% With No Bad News — DCF Models Say Fair Value Is Twice the Current Price

Ardelyx makes tenapanor, a drug for irritable bowel syndrome and a rare kidney condition called hyperphosphatemia — two areas Big Pharma largely ignored for decades. Its branded IBS pill, Ibsrela, crossed 100,000 patients in its first year on the market, with sales growth running triple digits quarter over quarter. Then, with no negative clinical data and no regulatory setback, the stock fell roughly 20% in a matter of days on pure momentum selling.

That kind of disconnect is what DCF — discounted cash flow — models are built to catch. Analysts running the numbers on Ardelyx's projected revenue peg fair value somewhere between $12 and $15 per share. The stock is currently trading under $6. The math behind that gap: FDA approval of tenapanor for dialysis patients has opened a potential path to Medicare reimbursement for as many as 8 million eligible users, and the company's patent protection on the drug runs to 2035, giving competitors a long wall to climb.

The risk is real. Biotech stocks at this size are binary by nature — one competitor approval or one coverage denial can reset expectations overnight. But the selloff here wasn't driven by either. It was driven by traders rotating out of small-cap biotech during a volatile stretch, and that kind of selling creates the kind of entry point that value-oriented traders spend months waiting for.

Gobble's Take: A 20% dip on zero bad news, a patent moat to 2035, and a DCF gap you could park a truck in — the market is handing you homework, not a warning.

Source: Yahoo Finance

Small Caps Are Quietly Lapping Every Other Index — And the Gap Is Getting Harder to Ignore

The S&P 500 gets the headlines, but the S&P SmallCap 600 is running a different race right now. Eighty-one percent of its components are trading above their 20-day moving average — the short-term technical benchmark traders use to gauge near-term momentum. That compares to 70% for mid-caps and just 60% for the Dow Jones Industrial Average. Stretch the window to 50 days and small caps still lead at 76%.

The reason isn't random. Small-cap companies tend to carry more floating-rate debt than the cash-rich mega-caps, which means they're more sensitive to interest rate moves in both directions. When borrowing costs fall — or when traders start pricing in future cuts — small caps get a disproportionate lift. Barchart's sector heat maps show the rotation in real time: scrappy industrials, regional banks, and smaller consumer names are absorbing money that's quietly leaving the Nasdaq's biggest winners.

Historically, this kind of breadth divergence — small caps leading on multiple timeframes while large-caps stagnate — has preceded broad market rallies. In the three most comparable setups since 2010, small caps outperformed large-caps by an average of roughly 20% over the following six months.

Gobble's Take: The mega-cap trade is getting crowded; the small-cap trade is getting started — and the charts are telling you which side of that equation to be on.

Source: Barchart.com

The S&P 500 Just Printed a Golden Cross at an All-Time High — That Combination Has a Track Record

The S&P 500 touched 7,168.61 recently, a new all-time high. That alone would be a headline. What makes it more interesting to traders is what's happening underneath: the index has just formed a golden cross, the technical pattern where the 50-day moving average crosses above the 200-day moving average. It's the chart signal that traders treat as a formal declaration that the medium-term trend has turned bullish.

The historical record on golden crosses is worth knowing. According to Fidelity's technical analysis research, this pattern has preceded S&P 500 gains averaging around 15% over the following six months in roughly 80% of occurrences since 2000. The setup is stronger when it happens near or above the 200-day average rather than deep in a recovery — which is exactly the current situation. The index has already recaptured the 6,000 level that marked its year-to-date low, and it's now extending above it with a confirmed cross in place.

Risks haven't disappeared. Geopolitical uncertainty and still-elevated rates create overhead. But pair the golden cross with the small-cap breadth data above — two distinct signals, from different parts of the market, pointing the same direction — and the setup starts to look less like optimism and more like structure.

Gobble's Take: Two independent signals — a golden cross and small-cap breadth leadership — agreeing at the same time is the market's version of a second opinion, and both say the same thing.

Sources: Trading Economics · Fidelity Investments

Quick Hits

• Semis lead the open: The S&P 500 and Nasdaq gapped higher as semiconductor stocks extended their Q4 earnings rally, with bulls holding control despite elevated volatility. MarketScreener
• Global funds rush back in: Equity funds recorded their largest weekly inflows in 15 weeks, pushing major indices within striking distance of records even as rate uncertainty lingers. MarketScreener

In Case You Missed It

Yesterday's top stories:

• Pharma Giant Daiichi Sankyo Delays Earnings, Stock Tanks 4%—Is This a Red Flag or Buy Signal?
• Mondi Q1 EBITDA Flatlines at €400M—Stock Dips 2%, But Packaging Demand Hints at Turnaround
• SLM Corp Swings Wild: Down 10% This Week, Now Trading at 9x Earnings—Value Trap or Student Loan Goldmine?